Insmed reports third-quarter 2023 financial results and provides business update

—arikayce® (amikacin liposome inhalation suspension) total revenue of $79.1 million for the third quarter of 2023 reflects highest quarter of sales since launch and 17% growth compared to the third quarter of 2022— —company reiterates full-year 2023 guidance range for global arikayce revenues of $295 million to $305 million— —insmed shares encouraging blended and blinded dose titration and safety and tolerability data from the phase 2 studies of tpip in ph-ild and pah, as well as blinded pulmonary vascular resistance (pvr) data from the pah study— —topline data from the phase 3 aspen trial of brensocatib in adult patients with bronchiectasis remains on track to read out in the second quarter of 2024— bridgewater, n.j. , oct. 26, 2023 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended september 30, 2023 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking